Table 2.

Analysis of inflammatory markers in patients with SCLC (n = 119).

	NLR	p	PLR	p	MLR	p	SII	p
Age		0.992		0.103		0.019		0.116
≤64	2.48 (1.00, 8.69)		143.59 (54.40, 390.00)		0.26 (0.04, 2.06)		580.32 (136.54, 2410.20)
>64	2.87 (0.30, 17.86)		117.91 (48.70, 561.19)		0.35 (0.08, 2.49)		496.51 (47.88, 2201.47)
Gender		0.005		0.062		0.007		0.007
Male	2.86 (2.01, 3.61)		132.71 (105.73, 168.22)		0.28 (0.22, 0.42)		565.83 (403.96, 802.21)
Female	1.72 (0.66, 14.68)		99.35 (48.70, 441.18)		0.21 (0.04, 0.47)		316.10 (123.22, 2201.47)
Smoking		0.036		0.125		0.079		0.025
Yes	2.78 (0.30, 16.40)		138.88 (54.40, 561.19)		0.29 (0.08, 2.49)		595.21 (47.88, 2410.20)
No	1.96 (0.66,17.86)		113.66 (48.70,366.97)		0.25 (0.04, 1.86)		425.75 (123.22, 1988.99)
Tumor Stage		0.001		0.019		0.002		0.007
LD-SCLC	2.23 (0.30, 6.87)		123.11 (48.70, 390.00)		0.26 (0.04, 2.06)		460.84 (47.88, 2410.20)
ED-SCLC	3.17 (1.00, 17.86)		149.33 (54.40, 561.19)		0.37 (0.08, 2.49)		737.47 (136.54, 2201.47)